Regeneron and University of Lausanne Publish Newomics M3 Emitters

BERKELEY, Calif.--(BUSINESS WIRE)--Newomics Inc., a commercial-stage biotechnology company that sells and develops mass spectrometry products and services, today announced that its award-winning multinozzle emitters (Newomics® M3 emitters) were featured in two publications from Regeneron Pharmaceuticals Inc. and the University of Lausanne, respectively.

“Versatile, Sensitive, and Robust Native LC-MS Platform for Intact Mass Analysis of Protein Drugs” by Regeneron was published on August 31, 2020, in Journal of the American Society for Mass Spectrometry (https://pubs.acs.org/doi/10.1021/jasms.0c00277). This article describes the development of an integrated LC-MS platform for native protein drug characterizations, enabled by Newomics multinozzle emitters. In particular, the developed platform can tolerate a wide range of LC flow rates and high salt concentrations, which are critical for accommodating different nLC methods. The platform also achieves online charge-reduction native MS, which improves the characterization of both heterogeneous and labile biomolecules.

“Robust and sensitive peptidomics workflow for plasma based on specific extraction, lipids removal, capillary LC setup and multinozzle ESI emitter” by University of Lausanne was published on September 8, 2020, in Talanta (https://www.sciencedirect.com/science/article/abs/pii/S0039914020309085). This article presents a new LC-MS workflow for determining native peptides in plasma at the low picomolar levels for clinical diagnosis, enabled by Newomics multinozzle emitters. The workflow has demonstrated utility in the first-time discovery of statherin-related peptides in blood with circadian oscillations.

“We are very excited that our multinozzle emitter technology has enabled our customers to develop new mass spectrometry platforms, in these cases, for antibody-based drug development and blood-based clinical diagnostics, respectively. We look forward to further optimizing our products and services to best meet the diverse needs from our customers,” said Dr. Daojing Wang, Founder and CEO, Newomics.

The Newomics multinozzle emitter technology enables optimization of sensitivity, throughput, and robustness for LC/MS by splitting the LC eluent evenly into multiple sprays, thereby dramatically enhancing the ionization efficiency. The applications of Newomics® M3 emitters have been successfully demonstrated in proteomics, lipidomics, and native MS analysis. The company has a robust product roadmap including additional lines of emitters, as well as the new MnESI (Microflow nanospray ESI) ion source scheduled for shipments in Q4, 2020.

About Newomics

Newomics Inc. is dedicated to creating and commercializing innovative (New) and integrative (Omics) platforms and solutions for precision medicine. The company’s first product, the M3 multinozzle emitter for LC-MS, delivers the robustness of microflow LC and the sensitivity of nanospray ionization MS. The plug-and-play M3 emitters are currently interfaced to diverse MS instruments and can be ordered at www.newomics.com.